<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00324649</url>
  </required_header>
  <id_info>
    <org_study_id>GS-ES-164-0154</org_study_id>
    <nct_id>NCT00324649</nct_id>
  </id_info>
  <brief_title>Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada</brief_title>
  <acronym>RECOMB</acronym>
  <official_title>Pilot Phase IV, Multicenter, Randomized, Open-label and Controlled Study to Assess the Evolution of Peripheral Body Fat Distribution After Switching From Zidovudine Containing Backbone to Truvada in HIV-1-infected Patients on HAART (RECOMB Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated changes in body fat distribution in human immunodeficiency virus type 1
      (HIV-1) infected participants who either switched from a zidovudine- plus lamivudine-
      containing highly active antiretroviral therapy (HAART) regimen to a regimen containing
      TruvadaÂ® (a fixed-dose combination tablet of emtricitabine [FTC, 200 mg] and tenofovir
      disoproxil fumarate [TDF, 300 mg]) or who remained on a zidovudine- plus
      lamivudine-containing regimen. Subjects continued their protease inhibitor (PI) or
      nonnucleoside reverse transcriptase inhibitor (NNRTI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard care for the treatment of HIV infection involves the use of a combination of three
      antiretroviral drugs. The initial recommended regimen in antiretroviral-naive patients
      according to therapeutic guidelines of the US Department of Health and Human Resources (DHHS)
      includes two nucleoside reverse transcriptase inhibitors (NRTIs) and a third drug from
      another class (PI or NRTI).

      The use of nucleoside analogues, especially stavudine and zidovudine, is associated with
      untoward side effects, including lipodystrophy hepatic steatosis/lactic acidosis syndrome,
      peripheral neuropathy, and anemia. However, Truvada has a low potential for both
      mitochondrial toxicity and fat distribution disturbances.

      As described in the Consensus Document of the Spanish Group for the Study of AIDS (GESIDA),
      and the AIDS National Plan from the Spanish Ministry of Health &quot;Recommendations on metabolic
      alterations and body fat distribution&quot;, studies should focus on the evaluation of body fat
      disturbances after antiretroviral drug substitutions, based on the basic assumption of
      virologic control of the patient and equivalence in potency of the new drug regarding
      virological control. In addition, studies based on selective substitution of antiretroviral
      drugs in HIV-1 infected patients under virological control, are recommended in the European
      Medicines Agency (EMA) in the &quot;Guideline on the clinical development of medicinal products
      for the treatment of HIV infection&quot;.

      In this study, stable, virologically controlled, HIV-1 infected participants receiving
      antiretroviral regimens containing zidovudine and lamivudine were randomized to switch to
      Truvada or to stay on their zidovudine- plus lamivudine-containing regimen. Participants in
      both groups continued the third drug of their antiretroviral regimen (either an NNRTI or PI).
      Changes in limb fat in the two groups were assessed using dual-energy x-ray absorptiometry
      (DEXA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Limb Fat at Week 48</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Limb fat was measured by DEXA. Change = Week 48 value minus baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mitochondrial DNA/Nuclear DNA Ratio (Oral Mucosa)</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change = Week 48 value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mitochondrial DNA/Nuclear DNA Ratio (Lymphocytes)</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change = Week 48 value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lactate Concentration</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change = Week 48 value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days for Which Participants Were Compliant With Study Drug</measure>
    <time_frame>Baseline to Week 72</time_frame>
    <description>Compliance = [1 - [(sum of days with a missed dose [per Question 6 study medication assessment questionnaire (SMAQ)])/(sum of days between SMAQ visits)]] *100 for visits with SMAQ data. An assessable visit is one where the number of missed days was reported [Question 6] and the number of days between SMAQ visits could be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Maintain Confirmed HIV-1 RNA &lt; 50 Copies/mL</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &gt; 50 and &lt; 400 Copies/mL</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Failure</measure>
    <time_frame>48 weeks</time_frame>
    <description>Virologic failure was defined as two consecutive HIV RNA values &gt; 400 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster Determinant 4 (CD4) Cell Count</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change = Week 48 value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Serum Triglycerides</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change = Week 48 value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Total Cholesterol</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change = Week 48 value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL)</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change = Week 48 value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL)</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change = Week 48 value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change = Week 48 value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Hematocrit</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change = Week 48 value minus baseline value expressed as median percent change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference/Hip Circumference Ratio</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change = Week 48 value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Adverse Event</measure>
    <time_frame>72 weeks</time_frame>
    <description>Participants with treatment-emergent adverse events were analyzed. Adverse events were defined as any untoward medical occurrence in a clinical investigation subject administered a medicinal product and which did not necessarily have a causal relationship with study treatment, and were categorized using the Medical Dictionary for Regulatory Activities (MedDRA) Version 11.
Treatment-emergent adverse events were events that met one of the following criteria:
Began or worsened in severity or relationship to study drug, on or after the date of the first dose of study drug and on or before the date of the last dose of study drug plus 30 days.
Had no recorded start date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinue the Study Prematurely (Before Week 48) Due to Adverse Events.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>HIV-1</condition>
  <arm_group>
    <arm_group_label>Truvada</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Truvada + NNRTI or PI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zidovudine/lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zidovudine/lamivudine + NNRTI or PI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>Truvada once daily with continuation of the current NNRTI or PI at randomization.</description>
    <arm_group_label>Truvada</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine/lamivudine</intervention_name>
    <description>Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.</description>
    <arm_group_label>Zidovudine/lamivudine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection documented by confirmed positive HIV-1 antibody test and/or positive
             polymerase chain reaction for HIV-1 ribonucleic acid (RNA).

          -  Adult patients (over 18 years of age).

          -  Current HAART regimen containing zidovudine + lamivudine at usual doses for at least 6
             months.

          -  Viral load &lt; 50 copies/mL on the last two consecutive determinations, under zidovudine
             + lamivudine containing HAART regimen.

          -  For women of childbearing potential, negative urine pregnancy test at screening visit.

          -  Agreement to take part in the study and sign the informed consent.

          -  Patients on lipid lowering treatment were allowed to participate in the study only if
             the lipid-lowering treatment (either statins or fibrates) was stable for at least 8
             weeks prior to screening and it was not expected to change during the first 3 months
             of the study.

        Exclusion Criteria:

          -  Patients on current FTC or TDF therapy.

          -  Patients with previous history of virological failure on an FTC or TDF-containing
             regimen.

          -  Patients receiving a non-registered antiretroviral drug.

          -  Patients receiving a triple-nucleoside antiretroviral combination.

          -  Hypersensitivity to one of the components of the dosage forms of TDF or FTC, or
             previous history of intolerance to one of those drugs.

          -  Known history of drug abuse or chronic alcohol consumption

          -  Women who were pregnant or breast feeding, or female of childbearing potential who did
             not use an adequate method of contraception according to the investigator's judgment.

          -  Active opportunistic infection or documented infection within the previous 4 weeks.

          -  Documented active malignant disease (excluding Kaposi sarcoma limited to the skin).

          -  Renal disease with creatinine clearance &lt; 50 mL/min.

          -  Concomitant use of nephrotoxic or immuno-suppressive drugs which could not be stopped
             without affecting the safety of the patient.

          -  Receiving on-going therapy with systemic corticosteroids, Interleukin-2 or
             chemotherapy.

          -  Patients who were not to be included in the study according to the investigator's
             criterion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Ferrer</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences, S.L.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gilead Sciences, S.L.</name>
      <address>
        <city>Madrid</city>
        <zip>E-28036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2006</study_first_submitted>
  <study_first_submitted_qc>May 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2006</study_first_posted>
  <results_first_submitted>March 30, 2009</results_first_submitted>
  <results_first_submitted_qc>March 30, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2009</results_first_posted>
  <last_update_submitted>August 13, 2015</last_update_submitted>
  <last_update_submitted_qc>August 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Truvada</title>
          <description>Truvada + nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI).</description>
        </group>
        <group group_id="P2">
          <title>Zidovudine/Lamivudine</title>
          <description>Zidovudine/lamivudine + nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Truvada</title>
          <description>Truvada + NNRTI or PI.</description>
        </group>
        <group group_id="B2">
          <title>Zidovudine/Lamivudine</title>
          <description>Zidovudine/lamivudine + NNRTI or PI.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="10.6"/>
                    <measurement group_id="B2" value="44" spread="7.4"/>
                    <measurement group_id="B3" value="44" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black, of African heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA Level</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 50 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to &lt; 400 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cluster determinant 4 (CD4) cell count</title>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="655.0" lower_limit="505.0" upper_limit="789.0"/>
                    <measurement group_id="B2" value="504.0" lower_limit="363.0" upper_limit="756.0"/>
                    <measurement group_id="B3" value="600.5" lower_limit="420.0" upper_limit="760.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total limb fat</title>
          <description>Measured using dual-energy x-ray absorptiometry (DEXA). Total limb fat is the sum of the left arm, right arm, left leg, and right leg.</description>
          <units>grams (g)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3565" lower_limit="511" upper_limit="15932"/>
                    <measurement group_id="B2" value="3589" lower_limit="903" upper_limit="28155"/>
                    <measurement group_id="B3" value="3589" lower_limit="511" upper_limit="28155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years on zidovudine (AZT)/lamivudine (3TC)</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" lower_limit="4.2" upper_limit="7.2"/>
                    <measurement group_id="B2" value="6.2" lower_limit="4.7" upper_limit="7.2"/>
                    <measurement group_id="B3" value="5.9" lower_limit="4.6" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Limb Fat at Week 48</title>
        <description>Limb fat was measured by DEXA. Change = Week 48 value minus baseline value.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Treated participants. Number of participants analyzed is those with baseline and post-baseline DEXA data. Last post-baseline observation carried forward (LOCF) method was used if the Week 48 limb fat value was missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Limb Fat at Week 48</title>
          <description>Limb fat was measured by DEXA. Change = Week 48 value minus baseline value.</description>
          <population>Treated participants. Number of participants analyzed is those with baseline and post-baseline DEXA data. Last post-baseline observation carried forward (LOCF) method was used if the Week 48 limb fat value was missing.</population>
          <units>grams (g)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392" lower_limit="-102" upper_limit="1056"/>
                    <measurement group_id="O2" value="-257" lower_limit="-751" upper_limit="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mitochondrial DNA/Nuclear DNA Ratio (Oral Mucosa)</title>
        <description>Change = Week 48 value minus baseline value.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Treated participants. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mitochondrial DNA/Nuclear DNA Ratio (Oral Mucosa)</title>
          <description>Change = Week 48 value minus baseline value.</description>
          <population>Treated participants. Missing values were excluded.</population>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0" lower_limit="20.0" upper_limit="212.0"/>
                    <measurement group_id="O2" value="97.0" lower_limit="20.0" upper_limit="197.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9713</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mitochondrial DNA/Nuclear DNA Ratio (Lymphocytes)</title>
        <description>Change = Week 48 value minus baseline value.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Treated participants. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mitochondrial DNA/Nuclear DNA Ratio (Lymphocytes)</title>
          <description>Change = Week 48 value minus baseline value.</description>
          <population>Treated participants. Missing values were excluded.</population>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" lower_limit="2.0" upper_limit="89.5"/>
                    <measurement group_id="O2" value="43.0" lower_limit="1.0" upper_limit="72.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9725</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lactate Concentration</title>
        <description>Change = Week 48 value minus baseline value.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Treated participants. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lactate Concentration</title>
          <description>Change = Week 48 value minus baseline value.</description>
          <population>Treated participants. Missing values were excluded.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" lower_limit="-0.55" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.09" lower_limit="-0.12" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0078</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days for Which Participants Were Compliant With Study Drug</title>
        <description>Compliance = [1 - [(sum of days with a missed dose [per Question 6 study medication assessment questionnaire (SMAQ)])/(sum of days between SMAQ visits)]] *100 for visits with SMAQ data. An assessable visit is one where the number of missed days was reported [Question 6] and the number of days between SMAQ visits could be calculated.</description>
        <time_frame>Baseline to Week 72</time_frame>
        <population>Treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days for Which Participants Were Compliant With Study Drug</title>
          <description>Compliance = [1 - [(sum of days with a missed dose [per Question 6 study medication assessment questionnaire (SMAQ)])/(sum of days between SMAQ visits)]] *100 for visits with SMAQ data. An assessable visit is one where the number of missed days was reported [Question 6] and the number of days between SMAQ visits could be calculated.</description>
          <population>Treated participants.</population>
          <units>Percentage of days with compliance</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: percentages of days with compliance in the two treatment groups are equal. Alternative Hypothesis: percentages of days with compliance in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6984</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Maintain Confirmed HIV-1 RNA &lt; 50 Copies/mL</title>
        <time_frame>48 weeks</time_frame>
        <population>Treated participants. Missing values were treated as failure (i.e., as HIV-1 RNA greater than or equal to 50 copies/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Maintain Confirmed HIV-1 RNA &lt; 50 Copies/mL</title>
          <population>Treated participants. Missing values were treated as failure (i.e., as HIV-1 RNA greater than or equal to 50 copies/mL).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: treatment is not associated with the observed virologic response.
Alternative Hypothesis: treatment is associated with the observed virologic response.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1165</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>No adjustments were made.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>29.4</ci_upper_limit>
            <estimate_desc>The difference is for Truvada minus zidovudine/lamivudine. The 95% confidence interval on the mean difference between treatment groups is based on the normal approximation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &gt; 50 and &lt; 400 Copies/mL</title>
        <time_frame>48 weeks</time_frame>
        <population>Treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &gt; 50 and &lt; 400 Copies/mL</title>
          <population>Treated participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Failure</title>
        <description>Virologic failure was defined as two consecutive HIV RNA values &gt; 400 copies/mL.</description>
        <time_frame>48 weeks</time_frame>
        <population>Treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Failure</title>
          <description>Virologic failure was defined as two consecutive HIV RNA values &gt; 400 copies/mL.</description>
          <population>Treated participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster Determinant 4 (CD4) Cell Count</title>
        <description>Change = Week 48 value minus baseline value.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Treated participants. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster Determinant 4 (CD4) Cell Count</title>
          <description>Change = Week 48 value minus baseline value.</description>
          <population>Treated participants. Missing values were excluded.</population>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" lower_limit="-6.5" upper_limit="159.0"/>
                    <measurement group_id="O2" value="9.0" lower_limit="-61.0" upper_limit="106.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0789</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Serum Triglycerides</title>
        <description>Change = Week 48 value minus baseline value.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Treated participants. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Serum Triglycerides</title>
          <description>Change = Week 48 value minus baseline value.</description>
          <population>Treated participants. Missing values were excluded.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="-31.0" upper_limit="17.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="-44.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9633</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Total Cholesterol</title>
        <description>Change = Week 48 value minus baseline value.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Treated participants. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Total Cholesterol</title>
          <description>Change = Week 48 value minus baseline value.</description>
          <population>Treated participants. Missing values were excluded.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="-12.0" upper_limit="12.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-19.0" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9686</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL)</title>
        <description>Change = Week 48 value minus baseline value.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Treated participants. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL)</title>
          <description>Change = Week 48 value minus baseline value.</description>
          <population>Treated participants. Missing values were excluded.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="-9.4" upper_limit="15.6"/>
                    <measurement group_id="O2" value="5.0" lower_limit="-14.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6638</p_value>
            <p_value_desc>No adjustments for multiple comparisons were performed.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL)</title>
        <description>Change = Week 48 value minus baseline value.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Treated participants. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL)</title>
          <description>Change = Week 48 value minus baseline value.</description>
          <population>Treated participants. Missing values were excluded.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-7.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-7.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2907</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin</title>
        <description>Change = Week 48 value minus baseline value.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Treated participants. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin</title>
          <description>Change = Week 48 value minus baseline value.</description>
          <population>Treated participants. Missing values were excluded.</population>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.0" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-0.5" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0072</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Hematocrit</title>
        <description>Change = Week 48 value minus baseline value expressed as median percent change.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Treated participants. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Hematocrit</title>
          <description>Change = Week 48 value minus baseline value expressed as median percent change.</description>
          <population>Treated participants. Missing values were excluded.</population>
          <units>Percent change in hematocrit</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.5" upper_limit="4.3"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-0.9" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference/Hip Circumference Ratio</title>
        <description>Change = Week 48 value minus baseline value.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Treated participants. Missing values were excluded. Assessment of waist and hip circumference was added to the study schedule via protocol amendment part way through the study. This resulted in small numbers of subjects having data available for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist Circumference/Hip Circumference Ratio</title>
          <description>Change = Week 48 value minus baseline value.</description>
          <population>Treated participants. Missing values were excluded. Assessment of waist and hip circumference was added to the study schedule via protocol amendment part way through the study. This resulted in small numbers of subjects having data available for this analysis.</population>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-0.03" upper_limit="0.02"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.01" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1785</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Adverse Event</title>
        <description>Participants with treatment-emergent adverse events were analyzed. Adverse events were defined as any untoward medical occurrence in a clinical investigation subject administered a medicinal product and which did not necessarily have a causal relationship with study treatment, and were categorized using the Medical Dictionary for Regulatory Activities (MedDRA) Version 11.
Treatment-emergent adverse events were events that met one of the following criteria:
Began or worsened in severity or relationship to study drug, on or after the date of the first dose of study drug and on or before the date of the last dose of study drug plus 30 days.
Had no recorded start date.</description>
        <time_frame>72 weeks</time_frame>
        <population>Treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Adverse Event</title>
          <description>Participants with treatment-emergent adverse events were analyzed. Adverse events were defined as any untoward medical occurrence in a clinical investigation subject administered a medicinal product and which did not necessarily have a causal relationship with study treatment, and were categorized using the Medical Dictionary for Regulatory Activities (MedDRA) Version 11.
Treatment-emergent adverse events were events that met one of the following criteria:
Began or worsened in severity or relationship to study drug, on or after the date of the first dose of study drug and on or before the date of the last dose of study drug plus 30 days.
Had no recorded start date.</description>
          <population>Treated participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Discontinue the Study Prematurely (Before Week 48) Due to Adverse Events.</title>
        <time_frame>48 weeks</time_frame>
        <population>Treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Zidovudine/Lamivudine</title>
            <description>Zidovudine/lamivudine + NNRTI or PI.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinue the Study Prematurely (Before Week 48) Due to Adverse Events.</title>
          <population>Treated participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Truvada</title>
          <description>Truvada + NNRTI or PI.</description>
        </group>
        <group group_id="E2">
          <title>Zidovudine/Lamivudine</title>
          <description>Zidovudine/lamivudine + NNRTI or PI.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4"/>
                <counts group_id="E2" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24"/>
                <counts group_id="E2" subjects_affected="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyperlactacidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other scholarly media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pedro Ferrer</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>+34 91 771 2478</phone>
      <email>pedro.ferrer@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

